{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:35:11Z","timestamp":1784230511964,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008865","name":"Xiamen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["CAN 2018\/362"],"award-info":[{"award-number":["CAN 2018\/362"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-06725"],"award-info":[{"award-number":["2022-06725"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-05973"],"award-info":[{"award-number":["2018-05973"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bioorg.2025.108424","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:09:48Z","timestamp":1743998988000},"page":"108424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia"],"prefix":"10.1016","volume":"160","author":[{"given":"Jingmei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2025.108424_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188666","article-title":"The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors","volume":"2022","author":"Friedman","year":"1877","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108424_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","article-title":"An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape","volume":"25","author":"Bystrom","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bioorg.2025.108424_bb0015","doi-asserted-by":"crossref","unstructured":"F. A. Lagunas-Rangel, V. Ch\u00e1vez-Valencia, FLT3-ITD and its current role in acute myeloid leukaemia, Med. Oncol. 34 (6), doi:https:\/\/doi.org\/10.1007\/s12032-017-0970-x.","DOI":"10.1007\/s12032-017-0970-x"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108424_bb0020","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2012.114","article-title":"Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia","volume":"26","author":"Swords","year":"2012","journal-title":"Leukemia"},{"issue":"32","key":"10.1016\/j.bioorg.2025.108424_bb0025","doi-asserted-by":"crossref","first-page":"51163","DOI":"10.18632\/oncotarget.9965","article-title":"An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia","volume":"7","author":"Lopez","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.bioorg.2025.108424_bb0030","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2015-11-683581","article-title":"Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6","volume":"127","author":"Uras","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108424_bb0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12859-018-2145-y","article-title":"Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6","volume":"19","author":"Buetti-Dinh","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.bioorg.2025.108424_bb0040","doi-asserted-by":"crossref","unstructured":"J. Yang, R. Friedman, Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia, Cancer Cell Int.. 23 (1), doi:https:\/\/doi.org\/10.1186\/s12935-023-03000-x.","DOI":"10.1186\/s12935-023-03000-x"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108424_bb0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.20517\/cdr.2022.130","article-title":"How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?","volume":"6","author":"Perrone","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108424_bb0050","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1039\/D2CP05549J","article-title":"Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase","volume":"25","author":"Freire","year":"2023","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108424_bb0055","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/prot.25368","article-title":"The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib","volume":"85","author":"Friedman","year":"2017","journal-title":"Proteins"},{"key":"10.1016\/j.bioorg.2025.108424_bb0060","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1111\/febs.15209","article-title":"Deciphering the molecular mechanism of FLT3 resistance mutations","volume":"287","author":"Georgoulia","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2025.108424_bb0065","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12935-021-01856-5","article-title":"Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioorg.2025.108424_bb0070","article-title":"Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis","volume":"41","author":"Yang","year":"2025","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.bioorg.2025.108424_bb0075","doi-asserted-by":"crossref","unstructured":"M. T. Gebru, H.-G. Wang, Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia, J. Hematol. Oncol. 13 (1), doi:https:\/\/doi.org\/10.1186\/s13045-020-00992-1.","DOI":"10.1186\/s13045-020-00992-1"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108424_bb0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11899-006-0020-9","article-title":"Targeting the c-kit receptor in the treatment of acute myelogenous leukemia","volume":"1","author":"Advani","year":"2006","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108424_bb0085","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1021\/acs.jmedchem.9b00223","article-title":"Identification of Pyrrolo[2,3]pyrimidine-based derivatives as potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia","volume":"62","author":"Yuan","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108424_bb0090","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2019.06.002","article-title":"Dual FLT3 inhibitors: against the drug resistance of acute myeloid leukemia in recent decade","volume":"178","author":"Yuan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108424_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1460","article-title":"Generalized Kohn-sham energy decomposition analysis and its applications","volume":"10","author":"Su","year":"2020","journal-title":"WIREs Comput. Mol. Sci."},{"issue":"32","key":"10.1016\/j.bioorg.2025.108424_bb0100","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/jcc.26765","article-title":"XEDA, a fast and multipurpose energy decomposition analysis program","volume":"42","author":"Tang","year":"2021","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.108424_bb0105","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1039\/b810189b","article-title":"Long-range corrected hybrid density functionals with damped atom-atom dispersion corrections","volume":"10","author":"Chai","year":"2008","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.bioorg.2025.108424_bb0110","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1039\/b508541a","article-title":"Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: design and assessment of accuracy","volume":"7","author":"Weigend","year":"2005","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108424_bb0115","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.108424_bb0120","doi-asserted-by":"crossref","unstructured":"S. K. Joshi, S. Sharzehi, J. Pittsenbarger, D. Bottomly, C. E. Tognon, S. K. McWeeney, B. J. Druker, E. Traer, A noncanonicalFLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance, Am. J. Hematol. 96 (7), doi:https:\/\/doi.org\/10.1002\/ajh.26174.","DOI":"10.1002\/ajh.26174"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108424_bb0125","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.bbagen.2019.01.011","article-title":"The catalytic activity of Abl1 single and compound mutations: implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia","volume":"1863","author":"Georgoulia","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.bioorg.2025.108424_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1563","article-title":"Computational studies of protein-drug binding affinity changes upon mutations in the drug target","volume":"12","author":"Friedman","year":"2022","journal-title":"WIREs Comput Mol Sci"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108424_bb0135","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering Precision Medicine through an International Consortium","volume":"7","author":"Consortium","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108424_bb0140","doi-asserted-by":"crossref","unstructured":"L. M\u00f6hrmann, A. Cuberi, S. Br\u00fcckmann, S. Stasik, L. C. Heukamp, M. Bornh\u00e4user, H. Glimm, G. Folprecht, Response to (K)RASG12C and EGFR Inhibition in a Patient With NRASG12C-Mutated Rectal Cancer, JCO Precis Oncol (7), doi:https:\/\/doi.org\/10.1200\/po.22.00666.","DOI":"10.1200\/PO.22.00666"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108424_bb0145","article-title":"A holistic view on c-kit in cancer: structure, signaling, pathophysiology and its inhibitors","volume":"1876","author":"Pathania","year":"2021","journal-title":"Biochim BiophysActa Rev Cancer"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108424_bb0150","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.bioorg.2025.108424_bb0155","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108424_bb0160","doi-asserted-by":"crossref","unstructured":"J. Yang, R. Friedman, Synergy and antagonism between azacitidine and FLT3 inhibitors, Comput. Biol. Med. 169 (2024) 107889, ISSN 0010-4825, doi:https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107889.","DOI":"10.1016\/j.compbiomed.2023.107889"},{"key":"10.1016\/j.bioorg.2025.108424_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102238","article-title":"Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of Nilotinib by co-binding of Asciminib","volume":"298","author":"Oruganti","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108424_bb0170","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/ijc.2910410325","article-title":"Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines","volume":"41","author":"Hong","year":"1988","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.108424_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1757-2215-4-21","article-title":"Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin","volume":"4","author":"Sherman-Baust","year":"2011","journal-title":"J. Ovarian Res."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108424_bb0180","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108424_bb0185","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.18632\/oncotarget.14342","article-title":"Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM\/AZA-1 and MOLM\/DEC-5","volume":"8","author":"Hur","year":"2016","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.bioorg.2025.108424_bb0190","doi-asserted-by":"crossref","first-page":"14664","DOI":"10.1021\/acs.jmedchem.1c01196","article-title":"Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108424_bb0195","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.jmedchem.7b01261","article-title":"Discovery of 4-((7-pyrimidin-4-yl)amino)-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-kinase inhibitor with potentially high efficiency against acute Myelocytic leukemia","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"issue":"Web Server issue","key":"10.1016\/j.bioorg.2025.108424_bb0200","doi-asserted-by":"crossref","first-page":"W270","DOI":"10.1093\/nar\/gkn314","article-title":"PBEQ-Solver for online visualization of electrostatic potential of biomolecules","volume":"36","author":"Jo","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108424_bb0205","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2015","journal-title":"J. Chem. Theory Comput."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108424_bb0210","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/jcc.24829","article-title":"CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules","volume":"38","author":"Kim","year":"2017","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.108424_bb0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcc.540040211","article-title":"CHARMM: a program for macromolecular energy, minimization, and dynamics calculations","volume":"4","author":"Brooks","year":"1983","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.108424_bb0220","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular simulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108424_bb0225","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2016","journal-title":"Nat. Methods"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108424_bb0230","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108424_bb0235","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1021\/ci300363c","article-title":"Automation of the CHARMM general force field (CGenFF) I: bond perception and atom typing","volume":"52","author":"Vanommeslaeghe","year":"2012","journal-title":"J. Chem. Inf. Model."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108424_bb0240","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1021\/ci3003649","article-title":"Automation of the CHARMM general force field (CGenFF) II: assignment of bonded parameters and partial atomic charges","volume":"52","author":"Vanommeslaeghe","year":"2012","journal-title":"J. Chem. Inf. Model."},{"issue":"20","key":"10.1016\/j.bioorg.2025.108424_bb0245","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1016\/j.bmc.2016.06.034","article-title":"Parametrization of halogen bonds in the CHARMM general force field: improved treatment of ligand\u2013protein interactions","volume":"24","author":"Guti\u00e9rrez","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108424_bb0250","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108424_bb0255","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1021\/jp500405s","article-title":"Energy decomposition scheme based on the generalized Kohn-sham scheme","volume":"118","author":"Su","year":"2014","journal-title":"J. Phys. Chem. A"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108424_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1606","article-title":"Software update: The ORCA program system- Version 5.0","volume":"12","author":"Neese","year":"2022","journal-title":"WIREs Comput. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108424_bb0265","doi-asserted-by":"crossref","DOI":"10.1007\/s00214-007-0310-x","article-title":"The M06 suite of density Functionals for Main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited States, and transition elements: two new Functionals and systematic testing of four M06 Functionals and twelve other Functionals","volume":"120","author":"Zhao","year":"2008","journal-title":"Theor. Chem. Accounts"},{"key":"10.1016\/j.bioorg.2025.108424_bb0270","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0301-0104(81)85090-2","article-title":"Electrostatic interaction of a solute with a continuum - a direct utilization of ab initio molecular potentials for the prevision of solvent effects","volume":"55","author":"Miertus","year":"1981","journal-title":"Chem. Phys."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825003049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825003049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:24:55Z","timestamp":1762223095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825003049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":54,"alternative-id":["S0045206825003049"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108424","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108424"}}